**PATENT** 

Neal Gutterson Paul Oeller Application No.: 09/924,197 Page 3

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Annette S. Parent Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: (415) 576-0200 Fax: (415) 576-0300

PIT

SF 1290918 v1

Neal Gutterson Paul Oeller Application No.: 09/924,197 Page 4

## **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please replace the paragraph beginning on page 20, line 4, with the following rewritten paragraph:

Oligonucleotides were used to amplify a fragment which is deleted at the 5' end of the PG ORF (deletes 111 amino acids at the amino terminus of PG) and contains convenient restriction sites for cloning into pKL3063 and performing subsequent cloning steps.

PG-5' (19-mer sense primer):

5'-CTGTTCAATCCATGGTTCC-3' (SEQ ID NO:2; note: the underlined bases differ from the native PG sequence and provide a NcoI site at the engineered ATG initiation codon).

PG-3' (31-mer antisense primer):

5'-GA[AGATCT]ATACTGCAGATTAATAATTATAC-3' (SEQ ID NO:3; note: the underlined bases differ from native PG sequence and provide a PstI site downstream of the TAA stop codon, a BglII site proximal to the engineered PstI site is indicated by brackets, and the stop codon is highlighted in bold letters)

SF 1290918 v1